NCT07929519 Clinical Characteristics, Treatment, Diagnostic Findings, and Outcomes of Tuberculous Meningitis in Indonesia, 2022-2025
| NCT ID | NCT07929519 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Ina-Respond |
| Condition | Tuberculous Meningitis |
| Study Type | OBSERVATIONAL |
| Enrollment | 300 participants |
| Start Date | 2026-09-24 |
| Primary Completion | 2027-08-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 300 participants in total. It began in 2026-09-24 with a primary completion date of 2027-08-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
TBM Study is a multicenter, observational, retrospective cohort study of Tuberculous Meningitis (TBM) patients who underwent treatment at the hospital during the 2022-2025 period. The goal of this study is to learn about the clinical characteristics, diagnostic findings, drug resistance profiles, treatment regimens, complications, and treatment outcomes of patients diagnosed with TBM who were admitted to the study hospitals between 2022 and 2025. This study uses retrospective data obtained from electronic medical records (EMR).
Eligibility Criteria
Inclusion Criteria: * Admited to the participating hospital sites between January 1, 2022, and December 31, 2025 * Have a discharge diagnosis of TBM (ICD-10 code A17.0) or documented TBM diagnosis in the hospital EMR system. * Have accessible data available in the EMR. Exclusion Criteria: None
Contact & Investigator
dr. Robert Sinto, SpPD,, K-PTI, DPhil, FINASIM, FHEA
PRINCIPAL INVESTIGATOR
Indonesia Research Partnership on Infectious Disease (INA-RESPOND)
Frequently Asked Questions
Who can join the NCT07929519 clinical trial?
This trial is open to participants of all sexes, studying Tuberculous Meningitis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07929519 currently recruiting?
Yes, NCT07929519 is actively recruiting participants. Contact the research team at mhazis@ina-respond.net for enrollment information.
Where is the NCT07929519 trial being conducted?
This trial is being conducted at Denpasar, Indonesia, Jakarta, Indonesia, Jakarta, Indonesia, Ambon City, Indonesia and 2 additional locations.
Who is sponsoring the NCT07929519 clinical trial?
NCT07929519 is sponsored by Ina-Respond. The principal investigator is dr. Robert Sinto, SpPD,, K-PTI, DPhil, FINASIM, FHEA at Indonesia Research Partnership on Infectious Disease (INA-RESPOND). The trial plans to enroll 300 participants.